$SYRE 8-K SEC Filings

Filed On	Filing
07 Oct 2026	8-K: Entry into a Material Definitive Agreement Introductory. Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,117,648 shares (the “Firm Shares”) of its c...
08 Sep 2026	8-K: Regulation FD Disclosure; Other Events Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
25 Aug 2026	8-K: Regulation FD Disclosure; Other Events
04 Aug 2026	8-K: Results of Operations and Financial Condition
15 Jun 2026	8-K: Regulation FD Disclosure; Other Events
01 Jun 2026	8-K: Other Events
29 May 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
05 May 2026	8-K: Results of Operations and Financial Condition
16 Apr 2026	8-K: Entry into a Material Definitive Agreement
13 Apr 2026	8-K: Results of Operations and Financial Condition; Other Events
13 Apr 2026	8-K: Regulation FD Disclosure; Other Events
19 Feb 2026	8-K: Results of Operations and Financial Condition
12 Jan 2026	8-K: Regulation FD Disclosure
04 Nov 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
15 Oct 2025	8-K: Entry into a Material Definitive Agreement
14 Oct 2025	8-K: Results of Operations and Financial Condition
05 Aug 2025	8-K: Results of Operations and Financial Condition
17 Jun 2025	8-K: Regulation FD Disclosure; Other Events
02 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
08 May 2025	8-K: Results of Operations and Financial Condition

Comments